DADC
BMY.RT

D.A. Davidson & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

D.A. Davidson & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,821
Closed -$12K – 1191
2020
Q4 		$12K Sell
17,821
-622
-3% -$1.32K ﹤0.01% 1017
2020
Q3 		$41K Sell
18,443
-80
-0.4% -$228 ﹤0.01% 945
2020
Q2 		$66K Sell
18,523
-4,465
-19% -$16.1K ﹤0.01% 916
2020
Q1 		$87K Sell
22,988
-1,017
-4% -$3.35K ﹤0.01% 947
2019
Q4 		$72K Buy
+24,005
New +$62.4K ﹤0.01% 990

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

D.A. Davidson & Co's BMY.RT Position: Q1 2021 in Review

D.A. Davidson & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 17,821 shares — an estimated $12K sold.

D.A. Davidson & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $87K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • D.A. Davidson & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • D.A. Davidson & Co sold 17,821 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $12K.
  • D.A. Davidson & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • D.A. Davidson & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $87K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on D.A. Davidson & Co's 13F filing for Q1 2021, filed 7 May 2021.